Which agent is indicated as adjunct therapy for HoFH?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which agent is indicated as adjunct therapy for HoFH?

In Homozygous Familial Hypercholesterolemia, LDL receptor function is severely impaired, so therapies that rely on upregulating or enhancing LDL receptor activity often fall short. Lomitapide stands out as adjunct therapy because it targets the production side of lipoproteins rather than the clearance through LDL receptors. By inhibiting microsomal triglyceride transfer protein, lomitapide reduces the assembly and secretion of apoB-containing lipoproteins—primarily VLDL in the liver and chylomicrons in the intestine. Fewer VLDL particles mean fewer LDL particles overall, lowering LDL-C even when LDL receptors are defective. This mechanism makes lomitapide particularly valuable in HoFH when standard therapies (like statins or PCSK9 inhibitors) have limited effect. Use is in combination with other lipid-lowering treatments, not as a sole therapy. Be mindful of potential hepatic side effects—fat buildup in the liver and liver enzyme elevations can occur—so liver monitoring and a fat-restricted diet are important. Drug interactions via CYP3A4 should also be considered.

In Homozygous Familial Hypercholesterolemia, LDL receptor function is severely impaired, so therapies that rely on upregulating or enhancing LDL receptor activity often fall short. Lomitapide stands out as adjunct therapy because it targets the production side of lipoproteins rather than the clearance through LDL receptors. By inhibiting microsomal triglyceride transfer protein, lomitapide reduces the assembly and secretion of apoB-containing lipoproteins—primarily VLDL in the liver and chylomicrons in the intestine. Fewer VLDL particles mean fewer LDL particles overall, lowering LDL-C even when LDL receptors are defective. This mechanism makes lomitapide particularly valuable in HoFH when standard therapies (like statins or PCSK9 inhibitors) have limited effect.

Use is in combination with other lipid-lowering treatments, not as a sole therapy. Be mindful of potential hepatic side effects—fat buildup in the liver and liver enzyme elevations can occur—so liver monitoring and a fat-restricted diet are important. Drug interactions via CYP3A4 should also be considered.

More practice questions